Q BioMed Inc. QBIO
Set alert
0.00 USD 0.00 0.00%
As of Apr 2, 9:30 AM ET
0.0001 Day range 0.0001
0.0001 52-week range 0.02505
- YTD
- 0.00%
- 1 year
- -50.00%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 14.51K
- Vol
- 5.70K
- Avg vol
- 376
- EPS
- -0.02
- P/E
- -0.01
More statistics
- Low
- 0.0001
- High
- 0.0001
- Earnings
- May 26, 2023
Next earnings
May 26, 2023
Expected May 26, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 16, 2023 | Feb 1, 2023 | 0.00 | -0.02 | — | — |
| May 26, 2023 | Nov 1, 2022 | 0.00 | — | — | — |
| Nov 3, 2022 | Aug 1, 2022 | 0.00 | -0.03 | — | — |
News
- Q Biomed (OTCMKTS:QBIO) vs. GeneDx (NASDAQ:WGS) Financial Comparison
- Establishment Labs (NASDAQ:ESTA) & Q Biomed (OTCMKTS:QBIO) Critical Contrast
- Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review
- Q Biomed (OTCMKTS:QBIO) & GoodRx (NASDAQ:GDRX) Financial Survey
- SBC Medical Group (NASDAQ:SBC) and Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast
- Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
- Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
- Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
- Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment
- Q BioMed reports Strontium89 sales revenue surge in shareholder update
Your note
Sign in to keep a note on QBIO — it syncs with the Stock Master app.